文献速递呼吸危重症与机械通气

血浆晚期糖基化终产物可溶性受体与血管生成素-2在儿童急性呼吸窘迫综合征中的验证

Validation of plasma soluble receptor of advanced glycation end-products and angiopoietin-2 in paediatric acute respiratory distress syndrome
RSS 订阅 · BMJ Open Respiratory Research

这项前瞻性观察研究纳入93例儿童急性呼吸窘迫综合征(PARDS)和117例非PARDS危重病患儿,验证血浆sRAGE与Ang-2对PARDS诊断及预后的关联。sRAGE在PARDS组高于非PARDS组、在非存活者高于存活者,且与PARDS诊断及ICU死亡独立相关;Ang-2仅在非存活者中升高,多变量模型中无独立关联。

要点

  • 血浆sRAGE在PARDS组高于非PARDS危重病组(2981 vs 1575 pg/mL,p=0.002)。
  • sRAGE在非存活者高于存活者(5323 vs 1601 pg/mL,p<0.001),与ICU死亡独立相关(aOR 1.02)。
  • Ang-2在非存活者高于存活者(3054 vs 1748 pg/mL,p=0.002),但多变量模型中无独立关联。

核心结论

  • 在ICU队列中,仅sRAGE与PARDS诊断及ICU死亡相关,控制混杂因素后关联仍存在。

研究设计与样本

  • 前瞻性观察研究,纳入93例PARDS患儿和117例非PARDS危重病患儿。
  • 采用酶联免疫吸附试验测定血浆sRAGE和Ang-2水平。
  • 比较PARDS与非PARDS、存活者与非存活者之间的差异。
  • 采用多变量logistic回归校正年龄和儿童死亡指数3评分后分析生物标志物与ICU死亡的关系。

主要发现

  • 血浆sRAGE在PARDS组高于非PARDS危重病组:2981(1027至6198)vs 1575(864至2994)pg/mL,p=0.002。
  • 血浆sRAGE在非存活者高于存活者:5323(1647至8261)vs 1601(864至3572)pg/mL,p<0.001。
  • 血浆Ang-2在非存活者高于存活者:3054(1760至6808)vs 1748(845至3868)pg/mL,p=0.002。
  • 血浆Ang-2在PARDS组与非PARDS组之间无差异。
  • 多变量模型中,sRAGE与PARDS诊断独立相关(aOR 1.01,95%CI 1.01至1.02;p=0.003),与ICU死亡独立相关(aOR 1.02,95%CI 1.01至1.03;p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives Paediatric acute respiratory distress syndrome (PARDS) is a heterogeneous condition and identifying a specific biomarker remains a challenge. We aimed to validate the association of plasma soluble receptor for advanced glycation end-products (sRAGE) and angiopoietin-2 (Ang-2) with PARDS diagnosis, and its prognostic performance. Methods This prospective observational study included children with PARDS and non-PARDS critical illness. Plasma sRAGE and Ang-2 levels were measured using enzyme-linked immunosorbent assays. Comparisons were made between PARDS versus non-PARDS critical illness and survivors versus non-survivors. Multivariable logistic regression was used to determine the association between biomarkers and intensive care unit (ICU) mortality after adjusting for age and the Pediatric Index of Mortality 3 score. Results 93 and 117 patients with PARDS and non-PARDS critical illness, respectively, were included in this study. Plasma sRAGE was higher in PARDS versus non-PARDS critical illness (2981 (1027 to 6198) vs 1575 (864 to 2994) pg/mL; p=0.002) and in non-survivors vs survivors (5323 (1647 to 8261) vs 1601 (864 to 3572); p<0.001). Plasma Ang-2 was elevated in non-survivors versus survivors (3054 (1760 to 6808) vs 1748 (845 to 3868); p=0.002), though there was no difference between PARDS and non-PARDS groups. In the multivariable model, sRAGE demonstrated an independent association with PARDS diagnosis (adjusted OR (aOR) 1.01 95% CI 1.01 to 1.02; p=0.003) and ICU mortality (aOR 1.02 (95% CI 1.01 to 1.03); p<0.001), whereas there was no association observed with Ang-2. Conclusion Within an ICU cohort, only sRAGE demonstrated an association with the diagnosis of PARDS and ICU mortality, which remained after controlling for confounders.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Validation of plasma soluble receptor of advanced glycation end-products and angiopoietin-2 in paediatric acute respiratory distress syndrome

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。